Clinical Trials Study
Copyright ©The Author(s) 2020.
World J Gastroenterol. Oct 28, 2020; 26(40): 6260-6269
Published online Oct 28, 2020. doi: 10.3748/wjg.v26.i40.6260
Table 1 Demographic and baseline characteristics, intent-to-treat population

9-12 yr old
13-16 yr old
All SPMC 1 dose × 2 (n = 32)
All PEG (n = 30)
n (%)
SPMC ½ dose × 2 (n = 16)
SPMC 1 dose × 2 (n = 16)
PEG (n = 16)
SPMC 1 dose × 2 (n = 16)
PEG (n = 14)
Age (yr), mean (SD)10.8 (1.0)10.5 (1.2)10.4 (1.2)15.0 (1.0)14.9 (0.9)12.8 (2.5)12.5 (2.5)
Female, n (%)11 (68.8)12 (75.0)8 (50.0)11 (68.8)11 (78.6)23 (71.9)19 (63.3)
White race, n (%)15 (93.8)16 (100)11 (68.8)15 (93.8)14 (100)31 (96.9)25 (83.3)
BMI (kg/m2), mean (SD) 19.0 (4.8)20.4 (5.3)19.4 (5.2)24.9 (7.0)23.1 (6.5)22.6 (6.5)21.1 (6.0)